Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — FY2026 Earnings Presentation
12 slides from Clinuvel Pharmaceuticals's earnings presentation, Aug 27, 2026
Slide 1: U.S. Expansion Supported by Strong Foundation
U.S. Expansion Supported by Strong Foundation Financial Year Ended 30 June 2026 Investor Briefings: 27 August – 4 September 2026 ASX: CUV | Nasdaq: CUVL | Börse Frankfurt: UR9
Slide 2: Forward-looking statement
Forward -looking statement CLINUVEL GROUP This release contains forward-looking statements, which reflect the current beliefs and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the expectations of CLINUVEL’s management. All statements other than statements
Slide 3: Financial performance
FY2026 Financial performance CONSOLIDATED ENTITY1 30 June 2026 Change • disciplined and balanced approach Revenues2 A$94m -1% • second consecutive year of $100m+ Revenues plus Interest and Other Income A$101m -4% total revenue Expenses A$53m -0.5% • 10 consecutive annual profits Net Profit Before In
Slide 4: Profitability
Year Ending 30 June (A$m) FY2026 100 60 Profitability 80 50 60 40 SCENESSE® in EPP1 – profitability 40 10-year CAGR revenues growth over a decade 31% 20 30 10-year CAGR expenses growth well controlled 18% 0 20 net profit margin 36% -20 10 -40 reinvestment RD&I 34% -60 0 return on equity 13% 2017 201
Slide 5: Expenses
FY2026 A$m FY2025 FY2026 Expenses Communications 8.9 –1.2% and Marketing 8.4 • Expenses well controlled at $A53m, 9.3 lower than 5- year average forecast General and +15.7% expenditures. Administrative 11.2 • Largest allocation of resources to R&D at 34% of total expenses; reduction 20.7 reflects cy
Slide 6: Strong balance sheet
Assets & liabilities (A$m) 300 FY2026 250 Strong balance sheet 200 150 Year ended 30 June 2025 2026 100 Total Assets A$272m A$295m +9% 50 Total Liabilities 0 • mainly trade creditors & tax A$31m A$22m -28% Assets Liabilities • debt-free FY2022 FY2023 FY2024 FY2025 FY2026 Cash Reserves 1 A$224m A$2
Slide 7: Building a sustainable, integrated biopharmaceutical company
Building a sustainable, integrated Profitable, focused, disciplined biopharmaceutical company Ten years profitable HQ – transitioning from • distribution of SCENESSE® for EPP Australia to U.S.A. • Europe, U.S.A., Israel, UK, Canada Principal operations – U.S.A., Strong balance sheet Europe, UK, Sing
Slide 8: Expanding American presence
Expanding American presence Significant opportunity to treat patients in need Increased American investor interest • Phase III vitiligo studies – systemic Rx [not immune suppressive] • SCENESSE® in EPP – direct distribution across 129 U.S. and 5 Canadian centers – 190 targeted (2027) • U.S. comprise
Slide 9: Commercial product and pipeline: melanocortins
Commercial product and pipeline: melanocortins Preclinical Phase I Phase II Phase III Commercial SCENESSE® (afamelanotide 16 mg) in adult EPP EEA, UK, CH, U.S.A., ISL, CAN, AUS SCENESSE® (afamelanotide 16 mg) in adolescent EPP Filing H2 2027 SCENESSE® (afamelanotide 16 mg) in adolescent and adult vi
Slide 10: Future outlook
Future outlook Foundation of 20 years Products, indications & healthcare solutions • 2 pharmaceutical products MELANOCORTIN HOUSE • 5 conditions • 3 PhotoCosmetic product lines TAM >US$300m Advancing RD&I Porphyria (EPP & VP) • novel sustained-release liquid peptide CUV: FY26 US$64m1 TAM >US$4.5b TA
Slide 11: Calendar & catalysts
Calendar & catalysts CY2026 H1 H2 CY2027 H1 H2 Health Canada: SCENESSE® Marketing Authorization decision √ EMA filing SCENESSE®: adolescent use in EPP Phase III, CUV105 vitiligo AAD’26 cases presented √ Top line results (Dec ‘26) Complete results Phase III, CUV107 vitiligo EMA Scientific Advice √ St
Slide 12: Thank you
Thank you Authorised for ASX release by the Managing Director on behalf of the Board of Directors of CLINUVEL PHARMACEUTICALS LTD Head of Investor Relations: Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD Investor Enquiries: https://www.clinuvel.com/investors/contact-us Level 22, 535 Bourke Street, M
CLINUVEL Pharmaceuticals — FY2026 Earnings Presentation on 6ix